#United States #San Francisco #Immunotherapy #Nektar Therapeutics #Rezpegaldesleukin

Nektar Therapeutics Announces Significant Public Offering

Nektar Therapeutics, a leading clinical-stage biotechnology firm, has disclosed the pricing for its upsized underwritten public offering, which amounts to an impressive $325 million. This strategic financial maneuver marks a pivotal moment for the company as it seeks to further its commitment to developing groundbreaking immunotherapy medicines.

Offering Details

On April 21, 2026, Nektar confirmed that it will offer 3,532,609 shares of its common stock at a set price of $92.00 each. This decision is anticipated to generate approximately $325 million in gross proceeds, enabling the company to bolster its research and development projects significantly. Notably, the offering is scheduled to close on April 23, 2026, subject to standard conditions.

Moreover, Nektar has provided underwriters with a valuable 30-day option to acquire an additional 529,891 shares at the same public offering price, which could further augment the potential funds raised.

Funding Utilization

The proceeds from this substantial offering are earmarked for various corporate purposes, primarily targeting research and development, clinical trial advancements, and manufacturing costs. Specifically, funds will support the ongoing Phase 3 trials for Nektar's lead drug candidate, rezpegaldesleukin, used in treating conditions like atopic dermatitis and alopecia areata.

Key Partnerships in Offering

Jefferies, TD Cowen, and Piper Sandler are at the forefront of managing this public offering as joint bookrunning managers, with Citigroup also contributing as a bookrunner. These partnerships signify a robust support network poised to guide Nektar through this critical phase of financing.

Understanding Nektar Therapeutics

Founded with an innovative spirit, Nektar Therapeutics focuses on creating solutions that address the root causes of immunological disorders. Its flagship product, rezpegaldesleukin (REZPEG), represents a first-in-class regulatory T-cell stimulator undergoing various trials targeting atopic dermatitis, Type 1 diabetes mellitus, and alopecia areata. Additionally, Nektar is nurturing developments in its pipeline, including other promising therapies and antibodies, aligning with its vision to revolutionize treatment protocols for chronic inflammatory diseases.

Legal Compliance and Forward-Looking Statements

The securities involved in the offering are being issued in accordance with a shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC). As such, all interested investors are encouraged to refer to the prospectus supplement and accompanying documents filed with the SEC.

Nektar is keen on maintaining transparency with investors, expressing that while the offering represents a significant opportunity, future conditions and market dynamics can influence actual outcomes. Therefore, potential investors should carefully consider these forward-looking statements.

Conclusion

The recent announcement by Nektar Therapeutics points to a strategic effort to enhance its financial foundation, enabling further advancements in innovative immunotherapy. By securing $325 million in capital, Nektar positions itself to make substantial progress in its ongoing clinical trials and potentially transform treatment modalities for autoimmune and chronic inflammatory diseases. The industry awaits the promising developments that may arise from this funding initiative.